Clinical trial · Interventional
An In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure
A Development of an In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure Using FTIR-ATR Spectroscopy
NCT03971032CI-TRIAL-00042060unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the current study is to develop a near real-time system using infrared spectroscopy, that will evaluate the histological specimen that was removed from the uterine cavity during the hysteroscopy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Uterine Cervical Neoplasm | Cervical Neoplasm | ALIAS | 0.90 |
| Uterine Neoplasms | Uterine Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hysteroscopy | Procedure | — | UNRESOLVED |
| Infrared Spectroscopy | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Women undergoing hysteroscopy
- description
- Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy
- interventionNames
- Procedure: Hysteroscopy
- Device: Infrared Spectroscopy
Primary outcomes (1)
- measure
- Comparison of infrared spectroscopy with routine histopathology
- timeFrame
- 3 years
- description
- Tissue smears that have undergone infrared spectroscopy during hysteroscopy will have a different spectral absorption than healthy tissue, thus indicating malignancy. These results will be compared to the results of routine histopathology to determine accuracy of spectroscopy to indicate malignancy.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing hysteroscopy Exclusion Criteria: * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.